FDA Commissioner Race: Biden Team Trying To Woo Reluctant Dems On Woodcock While Exploring New Options
The White House is trying to overcome some Senate Democrats’ opposition to Janet Woodcock as US FDA commissioner, while also looking for other candidates for the job. Josh Sharfstein, long thought to be Woodcock’s main competition, is not a strong contender.
You may also be interested in...
US FDA principal deputy commissioner Amy Abernethy is set to leave the agency by the end of April. The surprise news comes in the midst of the Biden administration still figuring out who they want to lead the FDA.
President Biden’s pick for HHS secretary, Xavier Becerra, is scheduled to face supporters and detractors at US Senate confirmation hearings next week.
Near tie goes to the US FDA? While almost every member of the Arthritis Advisory Committee agreed with agency’s assessment that ChemoCentryx’s trial of avacopan for ANCA vasculitis was poorly designed, making it hard to tease out the drug’s benefit-risk profile, about half were in favor of approval due to the potential to spare patients from the adverse effects of steroids. Others said the sponsor didn’t meet the agency’s standard for approval off just one pivotal study.